Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jurgens, D.
Right arrow Articles by Tefferi, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jurgens, D.
Right arrow Articles by Tefferi, A
Haematologica, Vol 89, Issue 11, 1394-1395
Copyright © 2004 by Ferrata Storti Foundation

Case Reports

Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia

DJ Jurgens, A Moreno-Aspitia, and A Tefferi

A comprehensive database inquiry at our institutions identified 11 patients with echocardiogram-documented idiopathic cardiomyopathy that post-dated a diagnosis of either polycythemia vera or essential thrombocythemia. Anagrelide therapy was temporally associated with the particular complication in 6 patients, all of whom experienced symptomatic and/or objective improvement after drug discontinuation.


This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
S. Gattenlohner, G. Ertl, H. Einsele, S. Kircher, H.-K. Muller-Hermelink, and A. Marx
Cardiac JAK2 Mutation V617F in a Patient with Cardiomyopathy and Myeloproliferative Disease
Ann Intern Med, July 1, 2008; 149(1): 69 - 71.
[Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2004 by the Ferrata Storti Foundation.